"可治疗而非可治愈":对无法治愈的癌症患者使用治疗导向语言时的权衡。

IF 4.8 2区 医学 Q1 ONCOLOGY Oncologist Pub Date : 2024-11-14 DOI:10.1093/oncolo/oyae296
Jason N Batten, Kristin M Kennedy, Bonnie O Wong, Stephanie A Kraft, William Hanks, David Magnus, Lidia Schapira
{"title":"\"可治疗而非可治愈\":对无法治愈的癌症患者使用治疗导向语言时的权衡。","authors":"Jason N Batten, Kristin M Kennedy, Bonnie O Wong, Stephanie A Kraft, William Hanks, David Magnus, Lidia Schapira","doi":"10.1093/oncolo/oyae296","DOIUrl":null,"url":null,"abstract":"<p><p>Treatment-oriented language is used by physicians to convey to patients that treatment is available for their cancer (eg, \"our usual treatment for this is…,\" \"we can treat this,\" \"your cancer is still treatable\"). For patients who have incurable cancer, especially for patients with a poor prognosis or who are at the end of life, it is important to understand how physicians conceptualize and use this \"everyday\" clinical language. We conducted a qualitative interview study with a multidisciplinary group of physicians (n = 30) who may care for patients with cancer at different points in their clinical course, from diagnosis to end of life. Physicians report a wide range of reasons for using treatment-oriented language in conversations with patients who have incurable cancer. However, physicians also reported concerns that this language can be ambiguous, can convey unintended positive prognostic information, and can shift attention away from important matters such as the non-curative nature of treatment or the inevitability of death. On the basis of these concerns, physicians should (1) consider whether their aims in using treatment-oriented language can be better achieved using other evidence-based communication strategies, and (2) recognize and proactively mitigate potential adverse effects of treatment-oriented language, which may manifest much later in the patient's clinical course.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"\\\"Treatable not curable\\\": trade-offs in the use of treatment-oriented language with patients who have incurable cancer.\",\"authors\":\"Jason N Batten, Kristin M Kennedy, Bonnie O Wong, Stephanie A Kraft, William Hanks, David Magnus, Lidia Schapira\",\"doi\":\"10.1093/oncolo/oyae296\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Treatment-oriented language is used by physicians to convey to patients that treatment is available for their cancer (eg, \\\"our usual treatment for this is…,\\\" \\\"we can treat this,\\\" \\\"your cancer is still treatable\\\"). For patients who have incurable cancer, especially for patients with a poor prognosis or who are at the end of life, it is important to understand how physicians conceptualize and use this \\\"everyday\\\" clinical language. We conducted a qualitative interview study with a multidisciplinary group of physicians (n = 30) who may care for patients with cancer at different points in their clinical course, from diagnosis to end of life. Physicians report a wide range of reasons for using treatment-oriented language in conversations with patients who have incurable cancer. However, physicians also reported concerns that this language can be ambiguous, can convey unintended positive prognostic information, and can shift attention away from important matters such as the non-curative nature of treatment or the inevitability of death. On the basis of these concerns, physicians should (1) consider whether their aims in using treatment-oriented language can be better achieved using other evidence-based communication strategies, and (2) recognize and proactively mitigate potential adverse effects of treatment-oriented language, which may manifest much later in the patient's clinical course.</p>\",\"PeriodicalId\":54686,\"journal\":{\"name\":\"Oncologist\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologist\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/oncolo/oyae296\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyae296","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

医生使用以治疗为导向的语言,向患者传达癌症是可以治疗的(例如,"我们通常的治疗方法是......"、"我们可以治疗"、"你的癌症仍然可以治疗")。对于无法治愈的癌症患者,尤其是预后不佳或生命垂危的患者,了解医生如何构思和使用这些 "日常 "临床语言非常重要。我们对一组多学科医生(n = 30)进行了定性访谈研究,这些医生可能在癌症患者从诊断到生命终结的不同临床阶段为其提供护理。医生们报告了在与无法治愈的癌症患者交谈时使用以治疗为导向的语言的各种原因。但是,医生们也表示担心这种语言可能会产生歧义,可能会无意中传达积极的预后信息,也可能会将注意力从治疗的非治愈性或死亡的不可避免性等重要问题上转移开。基于这些顾虑,医生应:(1)考虑使用以治疗为导向的语言的目的是否可以通过其他循证沟通策略更好地实现;(2)认识到并主动减轻以治疗为导向的语言的潜在不良影响,这些不良影响可能会在患者的临床过程中更晚些时候才显现出来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
"Treatable not curable": trade-offs in the use of treatment-oriented language with patients who have incurable cancer.

Treatment-oriented language is used by physicians to convey to patients that treatment is available for their cancer (eg, "our usual treatment for this is…," "we can treat this," "your cancer is still treatable"). For patients who have incurable cancer, especially for patients with a poor prognosis or who are at the end of life, it is important to understand how physicians conceptualize and use this "everyday" clinical language. We conducted a qualitative interview study with a multidisciplinary group of physicians (n = 30) who may care for patients with cancer at different points in their clinical course, from diagnosis to end of life. Physicians report a wide range of reasons for using treatment-oriented language in conversations with patients who have incurable cancer. However, physicians also reported concerns that this language can be ambiguous, can convey unintended positive prognostic information, and can shift attention away from important matters such as the non-curative nature of treatment or the inevitability of death. On the basis of these concerns, physicians should (1) consider whether their aims in using treatment-oriented language can be better achieved using other evidence-based communication strategies, and (2) recognize and proactively mitigate potential adverse effects of treatment-oriented language, which may manifest much later in the patient's clinical course.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncologist
Oncologist 医学-肿瘤学
CiteScore
10.40
自引率
3.40%
发文量
309
审稿时长
3-8 weeks
期刊介绍: The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.
期刊最新文献
Overestimation of clinical N-staging in microsatellite instable gastric cancers is associated with VEGF-C signaling and CD8+ T-cell dynamics. Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study. Immunotherapy benefits for large brain metastases in non-small cell lung cancer. Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1